Logo 1 Logo 2

Clinical Trial Details

Trial ID: L0124
Source ID: NCT04123613
Associated Drug: Dm199
Title: Multiple Doses of DM199 in Patients With Chronic Kidney Disease (REDUX)
Acronym:
Status: COMPLETED
Study Results: NO
Results:
Conditions: Kidney Diseases
Interventions: DRUG: DM199
Outcome Measures: Primary: Incidence of treatment emergent adverse events, Incidence, severity, and causality of adverse events, 12 weeks|Change in renal function, eGFR, 12 weeks|Change in urine albumin to creatinine ratio, UACR change from baseline, 12 weeks|Plasma measurements of DM199, Maximum plasma concentration of DM199, 12 weeks | Secondary: Tumor necrosis factor receptor 1 (TNF R1) concentration in plasma, change from baseline, TNF R1 change from baseline, 12 weeks|C-reactive protein (CRP) concentration in plasma, change from baseline, CRP change from baseline, 12 weeks|Matrix metalloproteainase-9 (MMP-9) concentration in plasma, change from baseline, MMP-9 change from baseline, 12 weeks|Vascular endothelial growth factor (VEGF) concentration in plasma, change from baseline, VEGF change from baseline, 12 weeks|Cystatin C concentration in plasma, change from baseline, Cystatin C change from baseline, 12 weeks|Prostaglandin E2 concentration in plasma, change from baseline, Prostaglandin E2 change from baseline, 12 weeks|Prostacyclin concentration in plasma, change from baseline, Prostacyclin change from baseline, 12 weeks
Sponsor/Collaborators: Sponsor: DiaMedica Therapeutics Inc
Gender: ALL
Age: ADULT, OLDER_ADULT
Phases: PHASE2
Enrollment: 79
Study Type: INTERVENTIONAL
Study Designs: Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
Start Date: 2019-12-17
Completion Date: 2022-03-16
Results First Posted:
Last Update Posted: 2022-03-31
Locations: Aventiv Research, Mesa, Arizona, 85210, United States|Amcis Research Center, Granada Hills, California, 91334, United States|IMD Clinical Trials Inc, Los Angeles, California, 90033, United States|Amicis Reserch Center, Northridge, California, 91324, United States|Innovative Healthcare Institute, Coral Springs, Florida, 33067, United States|Elixia at Florida Kidney Physicians-SE, Fort Lauderdale, Florida, 33308, United States|Pines Clinical Research-Hollywood, Hollywood, Florida, 33024, United States|Elixia at Florida Kidney Physicians, Temple Terrace, Florida, 33637, United States|Boise Kidney & Hypertension Institute, Meridian, Idaho, 83642, United States|Research by Design LLC, Chicago, Illinois, 60643, United States|New Orleans Center for Clinical Research, an AMR Company, New Orleans, Louisiana, 70119, United States|Elixia At Clincal Renal Associates, Upland, Pennsylvania, 19013, United States|Nephrotex Research Group, LLC, Dallas, Texas, 75231, United States|RDRI, DeSoto, Texas, 75115, United States
URL: https://clinicaltrials.gov/show/NCT04123613

Drug ID Drug Name Type DrugBank ID Targets Category Latest Progress